5 citations
,
November 1999 in “Medical Hypotheses” Minoxidil, a common hair loss treatment, might work by counteracting a hormone that reduces hair growth and promotes hair loss.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
January 2021 in “Faculty of 1000 Research Ltd” Phytochemicals may offer safer alternatives to synthetic drugs for prostate cancer treatment.
9 citations
,
August 2019 in “Journal of The European Academy of Dermatology and Venereology” Minoxidil activation by hair enzymes predicts treatment success for female hair loss.
3 citations
,
December 2024 in “Biomolecules & Therapeutics” Tanshinone compounds can help prevent hair loss caused by testosterone.
April 2011 in “Cancer Research” 20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.
February 2026 in “Revista Eletrônica Polidisciplinar Voos.” A balanced approach using dutasteride and Serenoa repens can improve hair transplant success by protecting follicles and minimizing side effects.
20 citations
,
March 1990 in “Archives of Dermatology” Nonimmunosuppressive cyclosporines might treat skin diseases by affecting cell growth.
November 2025 in “Journal of Investigative Dermatology”
2 citations
,
October 2020 in “Journal of Pharmacology and Experimental Therapeutics” Minoxidil does not work to inhibit lysyl hydroxylases in newborn mouse lungs.
The models can help find better inhibitors for conditions like baldness and prostate disorders.
January 2018 in “Haydarpaşa Numune Hastanesi tıp dergisi” Tamsulosin's sulfonamide group may contribute to floppy iris syndrome.
9 citations
,
September 2024 in “Scientific Reports” Cardamonin may help treat oral cancer by promoting cell death and stopping cancer cell growth.
1 citations
,
December 2021 in “Natural Product Research” β-sitosterol and brassicasterol may help treat hair loss.
8 citations
,
February 2010 in “Journal of Dermatology” A topical treatment safely and effectively reduced acne by causing targeted cell death in sebaceous glands without side effects.
9 citations
,
November 2013 in “BMC Pharmacology and Toxicology” Suppressing eIF4E can prevent hair loss from chemotherapy.
17 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
2 citations
,
April 2016 in “DOAJ (DOAJ: Directory of Open Access Journals)” The saw palmetto extract effectively inhibits an enzyme linked to prostate issues, showing promise for prostate health.
37 citations
,
May 1997 in “The Journal of Clinical Endocrinology & Metabolism” MK-386 lowers DHT in blood and skin but not in semen.
January 2018 in “日本薬理学会年会要旨集 =” Minoxidil may protect the brain from damage by preventing cell death and energy loss.
March 2023 in “Journal of Cosmetic Dermatology” Low-dose oral minoxidil improved hair growth when topical treatments failed.
1 citations
,
June 2021 in “Journal of Cosmetic Dermatology” Enzyme booster SULT1A1 greatly enhances hair regrowth with minoxidil.
27 citations
,
October 2001 in “Journal of Medicinal Chemistry” Researchers found new potential but less potent rat enzyme inhibitors using a 3D model.
15 citations
,
December 2014 in “Dermatology and therapy” Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
21 citations
,
August 1994 in “Clinical endocrinology” 5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
234 citations
,
September 2004 in “Clinical cancer research” BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
October 2025 in “CRC Press eBooks” 19 citations
,
September 2008 in “Journal of Cellular Physiology” Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.
2 citations
,
March 2012 in “Current opinion in urology” 5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
December 2013 in “The Journal of Urology”